CREMESP releases guidance on medicinal Cannabis
CREMESP publishes a technical analysis on medicinal Cannabis to guide physicians based on evidence. Access and check the guidelines for your practice!
28/07/2026 15h14
Python
# Generating a detailed long-form news article (~1000 words) based on the CREMESP material
# The document analyzed is "FÓRUM DE DISCUSSÃO SOBRE O CANABIDIOL - DIFERENÇA ENTRE O USO DA CANNABIS, CANABIDIOL E THC" by Amouni Mohmoud Mourad (CRF-SP / presentation material).
# Note: The prompt asks for a news article highlighting CREMESP releasing material on medical cannabis.
# Let's craft an extensive, highly informative, journalistic piece following inverted pyramid, neutral tone, detailed scientific/regulatory breakdown, ~1000 words.
news_html = """<!DOCTYPE html>
<html lang="pt-BR">
<head>
<meta charset="UTF-8">
<title>Expanded News: CREMESP and Medicinal Cannabis</title>
<style>
@page {
size: A4;
margin: 18mm 15mm;
background-color: #ffffff;
}
*, *::before, *::after {
box-sizing: border-box;
}
body {
font-family: 'Georgia', 'Times New Roman', serif;
color: #1a1a1a;
line-height: 1.65;
margin: 0;
padding: 0;
}
.header {
border-bottom: 2px solid #003366;
padding-bottom: 12px;
margin-bottom: 20px;
}
.kicker {
font-family: 'Helvetica Neue', Arial, sans-serif;
font-size: 10pt;
font-weight: 700;
color: #003366;
text-transform: uppercase;
letter-spacing: 0.8px;
margin-bottom: 6px;
}
h1 {
font-family: 'Helvetica Neue', Arial, sans-serif;
font-size: 21pt;
line-height: 1.25;
color: #111111;
margin: 0 0 10px 0;
font-weight: 700;
}
.subtitle {
font-family: 'Helvetica Neue', Arial, sans-serif;
font-size: 11.5pt;
line-height: 1.45;
color: #4a5568;
margin-bottom: 14px;
}
.byline {
font-family: 'Helvetica Neue', Arial, sans-serif;
font-size: 9pt;
color: #718096;
border-top: 1px solid #e2e8f0;
border-bottom: 1px solid #e2e8f0;
padding: 6px 0;
margin-bottom: 20px;
}
.byline span {
font-weight: bold;
color: #2d3748;
}
p {
font-size: 10.5pt;
text-align: justify;
margin-bottom: 14px;
text-indent: 0;
}
.lead {
font-size: 11pt;
font-weight: 500;
color: #1a202c;
line-height: 1.6;
}
h2 {
font-family: 'Helvetica Neue', Arial, sans-serif;
font-size: 13pt;
color: #003366;
margin-top: 22px;
margin-bottom: 10px;
border-left: 3px solid #003366;
padding-left: 8px;
}
blockquote {
margin: 16px 0;
padding: 10px 16px;
background-color: #f7fafc;
border-left: 4px solid #3182ce;
font-style: italic;
font-size: 10pt;
color: #2d3748;
}
.info-box {
background-color: #f8fafc;
border: 1px solid #cbd5e0;
border-radius: 4px;
padding: 14px 18px;
margin: 18px 0;
font-family: 'Helvetica Neue', Arial, sans-serif;
font-size: 9.5pt;
}
.info-box h3 {
margin-top: 0;
color: #1a202c;
font-size: 10.5pt;
margin-bottom: 8px;
}
.info-box ul {
margin: 0;
padding-left: 18px;
}
.info-box li {
margin-bottom: 4px;
}
</style>
</head>
<body>
<div class="header">
<div class="kicker">Health & Medical Regulation</div>
<h1>CREMESP releases comprehensive technical guidance on medicinal Cannabis and promotes evidence-based practice in Brazil</h1>
<div class="subtitle">Based on the neurobiology of the endocannabinoid system and the differentiation between THC and CBD, the document guides the medical community on safety criteria, pharmacology, and regulatory support.</div>
</div>
<div class="byline">
By <span>Leandro Maia</span> | Special for Health and Regulation Journalism
</div>
<div class="content">
<p class="lead">The Regional Medical Council of the State of São Paulo (CREMESP) has made public a technical guidance material focused on the therapeutic use of Cannabis and its active derivatives. This initiative arises at a decisive moment for Brazilian medicine, characterized by the continuous expansion of prescriptions and the search for clear guidelines by health professionals. The council's statement establishes explanatory guidelines that connect cannabinoid science to clinical practice and respect for the ethical and regulatory principles of the country.</p>
<p>The publication of the material is seen by the medical community as a watershed moment. In a historical context where the medicinal use of the plant was often accompanied by communication noise, legal uncertainties, and a lack of continuing education modules in medical schools, the direct action of the São Paulo council provides technical density and support for prescribers' actions.</p>
<h2>Botanical, Historical Aspects and the Dynamics of Phytochemicals</h2>
<p>The released document details that <i>Cannabis sativa</i> has a complex phytochemical composition comprising dozens of active compounds, of which at least 61 have been widely cataloged by the scientific literature as phytocannabinoids. Furthermore, the report establishes distinctions between botanical strains — such as <i>Cannabis sativa</i> and <i>Cannabis indica</i> — highlighting how genomic variability and environmental factors directly influence the concentration of active principles in the plant.</p>
<p>Variables such as seed type, soil profile, climatic conditions, exposure to light radiation, and air significantly alter the proportion of phytocannabinoids synthesized in the inflorescences, parts that concentrate the highest densities of glandular resin, compared to stems, stalks, and seeds. The document emphasizes that while street-grade illicit products have uncertain levels of Tetrahydrocannabinol (THC) — typically ranging from 1% to 5% — production for pharmaceutical purposes requires strict standardization, absence of contaminants, and absolute dosage control.</p>
<p>Historically, the plant has records of medicinal and textile use dating back to 2723 BC in China, followed by formal cataloging by Carl Linnaeus in 1753 and its spread through Europe in the 18th century and the Americas in the 19th century. In Brazil, although introduced in the late 18th century with a focus on fiber exploitation, it was in the second half of the 20th century — with the isolation of THC in 1964 — that modern pharmacological investigation gained definitive momentum.</p>
<h2>Neurobiological Foundation: The Endocannabinoid System</h2>
<p>One of the central pillars of the technical document presented to the medical community lies in the explanation of the Endocannabinoid System (ECS), a fundamental neuromodulatory network involved in maintaining bodily homeostasis. The material categorizes substances that interact with this system into three well-defined origins: phytocannabinoids (plant-derived), endocannabinoids (lipid compounds synthesized by the body, such as Anandamide), and synthetic cannabinoids developed in laboratories.</p>
<p>The scientific detailing exposes the distribution and mechanics of the two main G-protein coupled receptors identified in the human body:</p>
<div class="info-box">
<h3>Distribution and Function of Cannabinoid Receptors:</h3>
<ul>
<li><strong>CB1 Receptors:</strong> Predominate in the Central Nervous System (CNS). They are highly concentrated in the Cortex (cognitive functions), Hippocampus (memory consolidation), Hypothalamus (appetite modulation), Amygdala (processing emotions and anxiety), Basal Ganglia and Cerebellum (motor coordination), as well as the Brainstem and Nucleus Accumbens (reward circuit).</li>
<li><strong>CB2 Receptors:</strong> Exhibit predominantly peripheral distribution, being located mainly in the cells and tissues of the immune system, playing a crucial role in regulating inflammatory and immunomodulatory processes.</li>
</ul>
</div>
<h2>Pharmacological Differentiation: THC versus Cannabidiol (CBD)</h2>
<p>The released material emphasizes that the differentiation between the plant's components is crucial for informed clinical decision-making. The document contrasts the pharmacological profiles of the two most studied cannabinoids: Tetrahydrocannabinol ($\Delta^9$-THC) and Cannabidiol (CBD).</p>
<p>The $\Delta^9$-THC is primarily responsible for the psychoactive and euphoric properties of the plant, acting through the increase of presynaptic dopamine release in the medial prefrontal cortex. However, from a therapeutic perspective, THC demonstrates established efficacy as an orexigenic (appetite stimulant in cases of cachexia or in patients with HIV/AIDS and cancer), antiemetic (mitigating nausea and refractory vomiting resulting from chemotherapy), and central analgesic. The guidance warns of its potential adverse effects, which include transient alteration of recent memory, sedation, tachycardia, dry mouth, and the risk of inducing toxic psychoses in genetically vulnerable individuals.</p>
<p>On the other hand, Cannabidiol (CBD) stands out as a non-psychoactive compound, representing up to 40% of standardized plant extracts. CBD acts as a competitive antagonist or modulator of THC, attenuating the euphoria and potential anxiogenic effects of the latter. Research highlighted by the council points to a broad therapeutic spectrum of CBD, which includes anticonvulsant properties (in severe epileptic syndromes), anxiolytic, neuroprotective, antipsychotic, and immunosuppressive properties.</p>
<p>In the context of inflammation, the report highlights the mechanism of action of CBD in combating osteoarticular and autoimmune diseases: the molecule can inhibit the nuclear transcription factor $NF-\kappa B$, blocking the transcription of pro-inflammatory cytokines by macrophages and substantially reducing tissue inflammatory response.</p>
<h2>Clinical Applications and Registered Drugs in Brazil</h2>
<p>To substantiate everyday prescriptive practice, the publication lists the main drugs and pharmaceutical formulations with international and national regulation. Emphasis is placed on the transition from in natura use to the use of purified extracts or standardized molecules registered with regulatory agencies.</p>
<p>Among the medications cited as market references and clinical trials are <i>Marinol®</i> (Dronabinol) and <i>Cesamet®</i> (Nabilone), used globally as antiemetics and appetite stimulants. In Brazil, the regulatory highlight is directed towards <i>Mevatyl®</i> (known internationally as <i>Sativex®</i>), the first Cannabis-based product to obtain formal registration from the National Health Surveillance Agency (Anvisa).</p>
<p>Each spray of <i>Mevatyl®</i> delivers a balanced proportion containing 2.7 mg of $\Delta^9$-THC and 2.5 mg of Cannabidiol (CBD), primarily indicated for the relief of moderate to severe muscle stiffness and neuropathic pain associated with Multiple Sclerosis. The document, however, warns of essential contraindications and precautions described in the package insert: the need for strict caution in patients with a personal or family history of psychiatric disorders (such as schizophrenia) and the requirement for detailed assessment of renal, hepatic, and cardiovascular function before starting therapy.
Click here to access the document